Skip to content
10-Q

Quarterly Report

IGM Biosciences, Inc.

0000950170-24-055615

← back to feed
Filed
May 8, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Current Liabilities Q1 2024 · Mar 31, 2024 $37.93M
Current Liabilities Q1 2024 · Dec 31, 2023 $42.48M
Total Liabilities Q1 2024 · Mar 31, 2024 $214.88M
Total Liabilities Q1 2024 · Dec 31, 2023 $220.18M
Current Assets Q1 2024 · Mar 31, 2024 $302.75M
Current Assets Q1 2024 · Dec 31, 2023 $347.6M
Total Assets Q1 2024 · Mar 31, 2024 $376.13M
Total Assets Q1 2024 · Dec 31, 2023 $423.41M
Cash And Equivalents Q1 2024 · Dec 31, 2023 $112.52M
Cash And Equivalents Q1 2024 · Mar 31, 2023 $140.16M
Shares Diluted Q1 2024 · Mar 31, 2023 44.47M sh
Capex Q1 2024 · Mar 31, 2023 $3.94M
Operating Cash Flow Q1 2024 · Mar 31, 2023 −$51M
Stockholders Equity Q1 2024 · Mar 31, 2023 $239.43M
Stockholders Equity Q1 2024 · Dec 31, 2022 $287.26M
Eps Diluted Q1 2024 · Mar 31, 2023 −$1.33
Eps Basic Q1 2024 · Mar 31, 2023 −$1.33
Sga Expense Q1 2024 · Mar 31, 2023 $13M
Rd Expense Q1 2024 · Mar 31, 2023 $50.89M
Net Income Q1 2024 · Mar 31, 2023 −$59.31M
Operating Income Q1 2024 · Mar 31, 2023 −$63.37M